Details
Stereochemistry | ACHIRAL |
Molecular Formula | C30H35F2N3O |
Molecular Weight | 491.6152 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC=CC(C)=C1NC(=O)CN2CCN(CCCC(C3=CC=C(F)C=C3)C4=CC=C(F)C=C4)CC2
InChI
InChIKey=ZBIAKUMOEKILTF-UHFFFAOYSA-N
InChI=1S/C30H35F2N3O/c1-22-5-3-6-23(2)30(22)33-29(36)21-35-19-17-34(18-20-35)16-4-7-28(24-8-12-26(31)13-9-24)25-10-14-27(32)15-11-25/h3,5-6,8-15,28H,4,7,16-21H2,1-2H3,(H,33,36)
Molecular Formula | C30H35F2N3O |
Molecular Weight | 491.6152 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL240 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15135665 |
16.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | CLINIUM Approved UseAngina pectoris resulting from ischaemic heart disease. Prophylaxis and after-treatment (after the acute phase) of myocardial infarcation. |
PubMed
Title | Date | PubMed |
---|---|---|
Ventricular tachyarrhythmias induced by disopyramide and other similar anti-arrhythmic drugs. | 1981 Jun 6 |
|
Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. | 2006 Mar |
|
Identification of human Ether-à-go-go related gene modulators by three screening platforms in an academic drug-discovery setting. | 2010 Dec |
Sample Use Guides
In Vivo Use Guide
Sources: http://home.intekom.com/pharm/janssen/clinium.html
The dosage ranges between 2 and 4 tablets daily. Dosage should be adapted individually and started gradually as follows:
first week –1 tablet daily.
second week –1 tablet every morning and evening.
third week –1 tablet three times per day.
An appreciable beneficial effect may sometimes be manifest after a few days or weeks of treatment but the full therapeutic result can usually only be assessed after 6 months of treatment.
If no marked improvement is noticeable after 3 months then the dosage may gradually be increased to 6 tablets per day using as guidelines the therapeutic response, possible non-transient side-effects and ECG controls.
Tablets are preferably taken during meals. Gastrointestinal disturbances can be avoided by taking an antacid con-currently. Clinical findings indicate that uninterrupted therapy, at the optimum dosage level, must be maintained indefinitely to consolidate the favourable results.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2175795
The neuronal cell degeneration was Ca+(+)-dependent because, in the absence of extracellular Ca++, 16 hr of exposure to 30 microM veratridine failed to produce release of LDH. Ca++ antagonists, nonselective for slow Ca++ channels (flunarizine, cinnarizine, lidoflazine, prenylamine and bepridil) inhibited veratridine-induced release of LDH with IC50 values between 0.11 and 0.47 microM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:44:44 GMT 2023
by
admin
on
Sat Dec 16 16:44:44 GMT 2023
|
Record UNII |
J4ZHN3HBTE
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC08EX01
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
||
|
WHO-ATC |
C08EX01
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
||
|
NCI_THESAURUS |
C333
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
3926
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
PRIMARY | |||
|
CHEMBL92870
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
PRIMARY | |||
|
6390
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
PRIMARY | RxNorm | ||
|
DB13766
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
PRIMARY | |||
|
DTXSID6045377
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
PRIMARY | |||
|
3416-26-0
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
PRIMARY | |||
|
1580
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
PRIMARY | |||
|
D008013
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
PRIMARY | |||
|
SUB08509MIG
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
PRIMARY | |||
|
J4ZHN3HBTE
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
PRIMARY | |||
|
C81685
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
PRIMARY | |||
|
LIDOFLAZINE
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
PRIMARY | |||
|
m6807
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
PRIMARY | Merck Index | ||
|
1925
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
PRIMARY | |||
|
222-312-8
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
PRIMARY | |||
|
100000082311
Created by
admin on Sat Dec 16 16:44:44 GMT 2023 , Edited by admin on Sat Dec 16 16:44:44 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |